[Progress in the diagnosis and treatment of childhood AML].
There are about 180 cases of childhood acute myeloid leukemia (AML) in Japan annually. For differential diagnosis and risk stratification of AML treatment, different diagnostic methods such as morphology, immunophenotyping, chimeric gene, chromosome and gene analysis are essential. According to the guidelines of JSPHO (Japanese Society of Pediatric Hematology/Oncology), different treatments for APL, ML-DS, and de novo AML have been carried out according to the JPLSG (Japan Pediatric Leukemia and Lymphoma Study Group) protocols. Although the prognosis in childhood AML is as good as that in I-BFM (Europe) and COG or St. Jude (USA), new drugs are needed to achieve further improvement. The developments of treatments aimed at decreasing late complications and prognostic analysis focusing on new genes employing the next-generation sequencer are also needed.